# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:AGEN) with a Buy and maintains $40 price target.
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today...
Agenus has published results from a groundbreaking clinical trial in Nature Medicine, revealing the potential of a novel immuno...
HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:AGEN) with a Buy and maintains $40 price target.
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat variou...